In NSCLC, chemotherapeutic treatment can damage DNA through various mechanisms, the lack of functional BRCA1 can lead to increased

sensitivity of the tumor cells to molecular damage, demonstrating that BRCA1 represents a predictive marker of chemotherapy response in NSCLC [6]. Ribonucleotide reductase subunit M1 (RRM1) is located on chromosome segment 11p15.5, it is a region with a frequent loss of heterozygosity in NSCLC. It is a component of ribonucleotide reductase, which is required for deoxynucleotide production and is also the predominant cellular determinant of the efficacy of gemcitabine, which make it to be the molecular target of gemcitabine [7, 8]. Along with the use of antitubulin agents such this website as taxanes and vinorelbine, study shows there are a number of tubulin isotypes in humans, and found that class III β-tubulin (TUBB3) among them is expressed in a proportion and related to clinical outcome [9]. The expression of GSK2245840 supplier TUBB3 is associated with resistance of paclitaxel and docetaxel, no matter in vitro or in clinical research [10, 11]. Changes

of gene mRNA expression during carcinogenesis may lead impact of the diagnosis, treatment, and prevention of NSCLC, it is important to understand these changes. So, in this study, we use RT-PCR to examine the expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 in tumor samples from patients with resected NSCLC not receiving adjuvant chemotherapy. We analyzed the relationships of these genes expression in tumors about survival time and response to chemotherapy to determine whether the expression of these molecules could be used as prognostic factors of progression-free and overall survival in this cohort of

patients. Methods Patient data A total of 85 patients who underwent curative surgery for NSCLC between August 2007 and April 2009 were enrolled into this study, including 85 tumor tissues and 34 adjacent tissues respectively. Among them there were 60 males and 25 females, aged 24-84 (mean 57) years. According Methane monooxygenase to WHO Classification (2000), there were 25 squamous, 60 adenomatous, with 58 moderate and well differentiated (G1-G2) and 27 low differentiated (G3). Because there were only 4 cases of stage IV patients who all had surgery after single brain AZD2171 mouse metastasis resected firstly, and there were no patients of stage IIIb. On account of stage IV patients were too few, so we combined 48 cases as staged I-II and 37 III-IV based on the revised AJC staging for lung cancer (1997). 28 cases had intra-thoracic lymph node metastasis (N1-N2), and 57 were negative lymph node metastasis. Additional information of surgery and chemotherapy status were all showed in (Table 1). The paracancerous tissues (defined as more than 5 cm away from the carcinoma tissue) taken from 34 cases were used as controls.